The Bioinformatics Core Facility was established on September 2003, with the aim of helping scientists advance their research with cutting edge bioinformatics methodologies. The facility provides data analysis services, consultation and training to scientists at BGU and all over Israel. Our clients are both from academia and industry.
Our main areas of expertise include the design and analysis of experiments which use genomic technologies (e.g. Next Generation Sequencing, Mass spec proteomics & metabolomics, Nanostring technology and microarrays), as well as mining and re-analysis of publicly available datasets.
As a core facility, we are required to encompass an extremely wide range of research areas. So far, we have been involved in studies in human genetic disorders, infectious diseases, plant sciences, stem cells & development, applied agriculture, aquaculture, biomedicine & biotechnology and more.
We continuously learn and expand our set of skills and capabilities, to cope with the ever-growing range of applications of genomic technologies. We see ourselves as applied bioinformaticians, using existing software tools as much as possible, and developing new software when necessary.
As the large majority of our projects are unique in their own way, there is rarely a standard analysis. For each project we carefully select and test a specific set of software and parameters. Often, projects arrive to our door which are not even similar to anything we have done before.
Throughout the work on a project, we smoothly navigate from complex biological questions to complex computational analyses, and then return to the biologist with data and knowledge which he/she can comprehend. We go hand-in-hand with the scientists in designing their genomic-scale experiments, in interpreting them, and in exploring options for further research. Finally, we assist in writing grant proposals, and take part in writing the bioinformatics parts in articles submitted for publication.
Among our customers are scientists from all Israeli Universities, from government research institutes, from the Ministry of Health, and from a large number of companies.